RYBODYN AWARDED $1.3M DOW GRANT TO ADVANCE NOVEL ANTIBODY THERAPIES FOR LUNG CANCER

Positive

AI Analysis

Summary

RyboDyn received a $1.3M CDMRP competitive grant to advance novel antibody therapies for lung cancer targeting two cryptic cell-surface targets discovered using its AI-powered RyboCypher platform.

Outcome Details

$1.3M CDMRP grant award

Importance:4/10

Sentiment:

0.60

grant fundingantibody therapieslung cancerAI platformpreclinicalCDMRP

Related Companies

$SURF

Read the original article

Published by PR Newswire Biotech on July 9, 2026 10:05 AM

Read Original